Larimar Therapeutics Inc

+0.83 (+3.97%)
Earnings Announcements

Larimar Therapeutics Reports Q3 Loss Per Share $0.64

Published: 11/10/2020 13:24 GMT
Larimar Therapeutics Inc (LRMR) - Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results.
Q3 Loss per Share $0.64.
Topline Data From Phase 1 Clinical Trials for Treatment of Fa Are Expected in First Half of 2021.
Cash, Cash Equivalents, and Marketable Securities of $102.3 Million As of September 30, 2020.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.19

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.18

More details on our Analysts Page.